Stryker initiated with an Outperform at BMO Capital

BMO Capital initiated coverage of Stryker with an Outperform rating and $369 price target. The March 2026 cyberattack was an operational disruption, not a demand story, and hospital order books are full, 2026 guidance has been reaffirmed, and lost Q1 sales seem to have a clear recovery path through the remainder of 2026, the analyst tells investors in a research note. The firm added that it sees a particularly compelling entry point into a best-in-class MedTech franchise with shares trading below historical averages.